Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.80 |
| ▸ | HDAC4 | P56524 | 10/20 | 0.80 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.65 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20593625 | 0.92 | HDAC6 (0.72) | HDAC6HDAC4HDAC1HDAC8HDAC5 | |
| SCHEMBL19030821 | 0.91 | HDAC6 (0.71) | HDAC6HDAC4HDAC1HDAC8HDAC5 | |
| SCHEMBL14935019 | 0.90 | HDAC6 (0.76) | HDAC6HDAC4HDAC1HDAC8HDAC5 | |
| SCHEMBL20593509 | 0.90 | HDAC6 (0.76) | HDAC6HDAC4HDAC1HDAC8HDAC5 | |
| SCHEMBL20593559 | 0.89 | HDAC4 (0.70) | HDAC6HDAC4HDAC1HDAC8HDAC5 | |
| SCHEMBL14645445 | 0.89 | HDAC4 (1.00) | HDAC6HDAC4HDAC1HDAC8 | |
| SCHEMBL20593420 | 0.89 | HDAC4 (0.91) | HDAC6HDAC4HDAC1HDAC8HDAC5 | |
| SCHEMBL20593703 | 0.89 | HDAC6 (0.70) | HDAC6HDAC4HDAC1HDAC8HDAC5 | |
| SCHEMBL14918495 | 0.89 | HDAC6 (0.74) | HDAC6HDAC4HDAC1HDAC8HDAC5 | |
| SCHEMBL20593596 | 0.88 | HDAC6 (0.66) | HDAC6HDAC4HDAC1HDAC8HDAC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180370927-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370927-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | PRF1, MPO, NOX3 | HDAC6 648/4885HDAC4 1464/4885HDAC1 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.